A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Blood

• Publication date

  1993-09-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1182/BLOOD.V82.6.1767.1767PMID 7691236
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Soluble Recombinant Factor VIII Fragment Containing the A2 Domain Binds to Some Human Anti-Factor VIII Antibodies that Are not Detected by Immunoblotting

  1992cited by this paper
• A2 domain of human recombinant-derived factor VIII is required for procoagulant activity but not for thrombin cleavage.

  1992cited by this paper
• Characterization of the interaction between the A2 subunit and A1/A3-C1-C2 dimer in human factor VIIIa.

  1992cited by this paper
• Epitope mapping of human factor VIII inhibitor antibodies by site‐directed mutagenesis of a factor VIII polypeptide

  1992cited by this paper
• Coagulant properties of hybrid human/porcine factor VIII molecules.

  1992cited by this paper
• Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.

  1992cited by this paper
• Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog.

  1991cited by this paper
• Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit.

  1991cited by this paper
• Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells.

  1991cited by this paper
• Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine.

  1990cited by this paper
• Intersubunit fluorescence energy transfer in human factor VIII.

  1989cited by this paper
• Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid.

  1989cited by this paper
• Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization.

  1989cited by this paper
• Association of the factor VIII light chain with von Willebrand factor.

  1988cited by this paper
• Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli.

  1988cited by this paper
• A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures.

  1987cited by this paper
• F VIII Subunits: Purification and Antigenic Properties

  1987cited by this paper
• The interaction of rDNA factor VIII, factor VIIIdes-797-1562 and factor VIIIdes-797-1562-derived peptides with phospholipid.

  1987cited by this paper
• The Production and Characterisation of a Panel of Ten Murine Monoclonal Antibodies to Human Procoagulant Factor VIII

  1986cited by this paper
• A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity.

  1986cited by this paper
• Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity.

  1986cited by this paper
• The functional domains of coagulation factor VIII:C.

  1986cited by this paper
• Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments.

  1985cited by this paper
• Expression of active human factor VIII from recombinant DNA clones

  1984cited by this paper
• Structure of human factor VIII

  1984cited by this paper
• Thrombin proteolysis of purified factor viii procoagulant protein: correlation of activation with generation of a specific polypeptide.

  1983cited by this paper
• Monoclonal antibodies to human procoagulant factor VIII.

  1983cited by this paper
• SV40-transformed simian cells support the replication of early SV40 mutants.

  1981cited by this paper

• A Comparative Review on the Production of Factor VIII in Human and Non-human Hosts.

  2025cites this paper
• Comprehensive Domain-Specific Analysis and IgG Profiling of anti-FVIII Antibodies using a bead-based multiplex immunoassay.

  2024cites this paper
• Hybrid human‐porcine factor VIII proteins partially escape the inhibitory effects of anti‐factor VIII inhibitor alloantibodies having A2 or C2 domain specificity

  2023cites this paper
• Bacterial Production of Recombinant Coagulation Factor VIII Domains

  2023influential citation
• Usefulness of anti-factor VIII IgG ELISA in acquired hemophilia A follow-up

  2022cites this paper
• Involvement of antifactor VIII autoantibodies specificity in the outcome of inhibitor eradication therapies in acquired hemophilia a patients

  2019cites this paper
• Factor VIII

  2018cites this paper
• Development of a novel automated screening method for detection of FVIII Inhibitors

  2017cites this paper
• Achievements, challenges and unmet needs for haemophilia patients with inhibitors

  2016cites this paper
• Detection and Prediction of Factor VIII Antibody Formation in Congenital and Acquired Haemophilia A

  2016cites this paper
• Prevalence of Inhibitors in Patients with Hemophilia Treated with Factor VIII or IX Transfusion in Coimbatore Medical College Hospital

  2015cites this paper
• Acquired Hemophilia A: A Frequently Overlooked Autoimmune Hemorrhagic Disorder

  2014cites this paper
• Caracterização das alterações genéticas em hemofílicos A graves do Rio Grande do Sul

  2012cites this paper
• UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL INSTITUTO DE BIOCIÊNCIAS DEPARTAMENTO DE GENÉTICA PROGRAMA DE PÓS-GRADUAÇÃO EM GENÉTICA E BIOLOGIA MOLECULAR CARACTERIZAÇÃO DAS ALTERAÇÕES GENÉTICAS EM HEMOFÍLICOS A GRAVES DO RIO GRANDE DO SUL

  2012cites this paper
• Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors

  2011cites this paper
• Acquired hemophilia A.

  2011cites this paper
• hemophilia A mice by mutagenesis of the A2 domain B-cell epitope Reduction of the inhibitory antibody response to human factor VIII in

  2010cites this paper
• Endocytic receptor for pro-coagulant factor VIII: Relevance to inhibitor formation

  2010cites this paper
• Polimorfismos em genes envolvidos na regulação do sistema imune e o risco de desenvolvimento de inibidores em hemofílicos A graves

  2010cites this paper
• B-Cell and T-Cell Epitopes in Anti-factor VIII Immune Responses

  2009cites this paper
• Characteristics, Mechanisms of Action, and Epitope Mapping of Anti-factor VIII Antibodies

  2009cites this paper
• Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains

  2009cites this paper
• Management of Haemophilia A-Inhibitor Patients: Clinical and Regulatory Perspectives

  2009cites this paper
• DESENVOLVIMENTO DE INIBIDORES CONTRA O FVIII EM HEMOFÍLICOS A DO TIPO GRAVE NO RIO GRANDE DO SUL.

  2008cites this paper
• Peptides derived from a secretory yeast library restore factor VIII activity in the presence of an inhibitory antibody

  2007cites this paper
• Mapping of FVIII inhibitor epitopes using cellulose-bound synthetic peptide arrays.

  2006cites this paper
• Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope.

  2004cites this paper
• Charakterisierung von Faktor-VIII-Antikörperepitopen mit Faktor-VIII-Peptid-Bibliotheken

  2003cites this paper
• The cDNA and Derived Amino Acid Sequence of Porcine Factor VI 11 By

  2002cites this paper
• Molecular Characterization of the Immune Response to Factor VIII

  2002cites this paper
• The concept of idiotypic vaccination against factor VIII inhibitors in haemophilia A

  2002cites this paper
• Characterization of antibodies to coagulation factor VIII

  2002cites this paper
• Optimization of factor VIII replacement therapy: can structural studies help in evading antibody inhibitors?

  2002cites this paper
• New Characteristics of Anti-Factor VIII Inhibitor Antibody Epitopes and Unusual Immune Responses to Factor VIII

  2002cites this paper
• Pathophysiology of inhibitors to factor VIII in patients with haemophilia A

  2002cites this paper
• In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.

  2001cites this paper
• Factor VIII Arg2304 → His Binds to Phosphatidylserine and Is a Functional Cofactor in the Factor X-ase Complex

  2001cites this paper
• Properties of Anti-Factor VIII Inhibitor Antibodies in Hemophilia A Patients

  2000cites this paper
• An Alloantibody Recognizing the FVIII A1 Domain in a Patient with CRM Reduced Haemophilia A due to Deletion of a Large Portion of the A1 Domain DNA Sequence

  2000cites this paper
• Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG.

  2000cites this paper
• Correlation between Factor VIII Genotype and Inhibitor Development in Hemophilia A

  2000cites this paper
• Partial Correction of Murine Hemophilia A with Neo-Antigenic Murine Factor VIII

  2000cites this paper
• Natural Antibodies to Factor VIII

  2000cites this paper
• Phage Display Technology: A Tool to Explore the Diversity of Inhibitors to Blood Coagulation Factor VIII

  2000cites this paper
• Properties of human antibodies to factor VIII defined by phage display

  2000cites this paper
• Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG

  2000cites this paper
• Characterization of Factor VIII B-Cell Inhibitory Epitopes

  1999cites this paper
• Inhibitors in German Hemophilia A Patients Treated with a Double Virus Inactivated Factor VIII Concentrate Bind to the C2 Domain of FVIII Light Chain

  1999cites this paper
• Human Inhibitor Antibodies Specific for the Factor VIII A2 Domain Disrupt the Interaction between the Subunit and Factor IXa*

  1999cites this paper
• Autoimmune factor VIII inhibitors.

  1999cites this paper
• Identification of a factor VIII peptide, residues 2315–2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect

  1999cites this paper
• Why do inhibitors arise in patients with haemophilia A?

  1999cites this paper
• Longitudinal Analysis of Factor VIII Inhibitors in a Previously Untreated Mild Haemophilia A Patient with an Arg593→Cys Substitution

  1999cites this paper
• Factor VIII Inhibitors in Mild and Moderate-severity Haemophilia A

  1998cites this paper
• Alternatives to Human Blood and Blood Resources

  1998cites this paper
• A human alloantibody interferes with binding of factor IXa to the factor VIII light chain.

  1998cites this paper
• Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII.

  1998cites this paper
• Modification of Factor VIII in Therapeutic Concentrates after Virus Inactivation by Solvent-Detergent and Pasteurisation

  1998cites this paper
• Factor VIII inhibitors in mild and moderate‐severity haemophilia A

  1998cites this paper
• Dominant C2 Domain Epitope Specificity of Inhibitor Antibodies Elicited by a Heat Pasteurized Product, Factor VIII CPS-P, in Previously Treated Hemophilia A Patients without Inhibitors

  1998cites this paper
• Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation.

  1997cites this paper
• Früherkennung von Hemmkörpern mit Hilfe der Immunpräzipitationsmethode

  1997cites this paper
• Acquired hemophilia and its treatment.

  1997cites this paper
• The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups.

  1997cites this paper
• Identification of Novel Factor VIII Inhibitor Epitopes using Synthetic Peptide Arrays

  1997cites this paper
• Analysis of the Human Factor VIII A2 Inhibitor Epitope by Alanine Scanning Mutagenesis*

  1997cites this paper
• Human Anti‐Factor VIII Antibodies: Epitope Localization and Inhibitory Function

  1996cites this paper
• Interferon‐γ secretion defects in haemophilia A patients receiving highly purified plasma‐derived or recombinant factor VIII

  1996cites this paper
• Factor VIII Inhibitor Antibodies with C2 Domain Specificity Are Less inhibitory to Factor VIII Complexed with von Willebrand Factor

  1996cites this paper
• The cDNA and derived amino acid sequence of porcine factor VIII.

  1996cites this paper
• Acquired inhibitors.

  1996cites this paper
• 9 Acquired inhibitors

  1996cites this paper
• Induction of Human Factor VIII Inhibitors in Rats 2: Fine Mapping of Rat anti-Human rFVIII Antibodies

  1996cites this paper
• Activated Protein C-catalyzed Proteolysis of Factor VIIIa Alters Its Interactions within Factor Xase (*)

  1996cites this paper
• Immunoblot cross-reactivity of factor VIII inhibitors with porcine factor VIII.

  1995cites this paper
• A Mechanism for Inhibition of Factor VIII Binding to Phospholipid by von Willebrand Factor (*)

  1995cites this paper
• Factor VIII inhibitors

  1995cites this paper
• Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site.

  1995cites this paper
• Immunogenetics of the human immune response to factor VIII.

  1995cites this paper
• Autoantibody to factor VIII that has less reactivity to factor Vlll/von Willebrand Factor Complex

  1995cites this paper
• Epitope specificity and functional characterization of factor VIII inhibitors.

  1995cites this paper
• Structure and function of Factor VIII.

  1995cites this paper
• Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the A2 Domain of Human Factor VIII (*)

  1995cites this paper
• Progress in the Understanding of Factor VIII Inhibitors

  1994cites this paper
• Acquired hemophilia.

  1994cites this paper
• Inhibition of human factor VIIIa by anti-A2 subunit antibodies.

  1994cites this paper
• Factor VIII inhibitors: structure and function in autoantibody and hemophilia A patients.

  1994cites this paper
• Elimination of a major inhibitor epitope in factor VIII.

  1994cites this paper